Singapore approves clinical trial to 'study Lianhua Qingwen treatment of mild COVID-19 in adults'
The publication of the article and its exposure on Chinese media and social networks took a heavy toll on the drug's reputation and the company that produces it, with its share price falling 6.7 billion yuan ($1.05 billion) in one day. In November, the announcement of revised rules on the coronavirus outbreak helped share prices recover.
In Macau, the health bureau that distributes drugs to...
0 Comments
0 Shares
924 Views
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian